Rates of VTE by stage stratified by treatment
| . | Events . | Person-years* . | Rate† . | 95% CI . | Univariable . | Multivariable‡ . | ||
|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | HR . | 95% CI . | |||||
| No active therapy§ | ||||||||
| Local disease | 160 | 29.99 | 5.3 | 4.6-6.2 | Ref | Ref | ||
| Regional disease | 113 | 14.94 | 7.6 | 6.3-9.1 | 1.4 | 1.1-1.8 | 1.4 | 1.1-1.8 |
| Distant metastases | 18 | 1.03 | 17.5 | 11.0-27.7 | 3.2 | 2.0-5.2 | 2.5 | 1.6-4.2 |
| Unknown | 170 | 22.67 | 7.5 | 6.5-8.7 | 1.4 | 1.1-1.8 | 1.2 | 1.0-1.6 |
| Active chemotherapy|| | ||||||||
| Local disease | 27 | 0.43 | 63.0 | 43.2-91.9 | Ref | Ref | ||
| Regional disease | 38 | 0.74 | 51.3 | 37.3-70.5 | 0.8 | 0.5-1.3 | 0.8 | 0.5-1.2 |
| Distant metastases | —¶ | —¶ | 26.2 | 6.6-104.8 | 0.4 | 0.1-1.7 | 0.3 | 0.1-1.4 |
| Unknown | 30 | 0.46 | 65.7 | 45.9-93.9 | 1.1 | 0.6-1.8 | 1.0 | 0.6-1.7 |
| Active surgery# | ||||||||
| Local disease | 26 | 0.92 | 28.1 | 19.2-41.3 | Ref | Ref | ||
| Regional disease | 9 | 0.52 | 17.2 | 8.9-33.0 | 0.6 | 0.3-1.3 | 0.6 | 0.3-1.4 |
| Distant metastases | —¶ | —¶ | 24.2 | 3.4-171.5 | 0.9 | 0.1-6.4 | 0.8 | 0.1-5.7 |
| Unknown | 14 | 0.65 | 21.5 | 12.7-36.3 | 0.8 | 0.4-1.5 | 0.7 | 0.4-1.4 |
| . | Events . | Person-years* . | Rate† . | 95% CI . | Univariable . | Multivariable‡ . | ||
|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | HR . | 95% CI . | |||||
| No active therapy§ | ||||||||
| Local disease | 160 | 29.99 | 5.3 | 4.6-6.2 | Ref | Ref | ||
| Regional disease | 113 | 14.94 | 7.6 | 6.3-9.1 | 1.4 | 1.1-1.8 | 1.4 | 1.1-1.8 |
| Distant metastases | 18 | 1.03 | 17.5 | 11.0-27.7 | 3.2 | 2.0-5.2 | 2.5 | 1.6-4.2 |
| Unknown | 170 | 22.67 | 7.5 | 6.5-8.7 | 1.4 | 1.1-1.8 | 1.2 | 1.0-1.6 |
| Active chemotherapy|| | ||||||||
| Local disease | 27 | 0.43 | 63.0 | 43.2-91.9 | Ref | Ref | ||
| Regional disease | 38 | 0.74 | 51.3 | 37.3-70.5 | 0.8 | 0.5-1.3 | 0.8 | 0.5-1.2 |
| Distant metastases | —¶ | —¶ | 26.2 | 6.6-104.8 | 0.4 | 0.1-1.7 | 0.3 | 0.1-1.4 |
| Unknown | 30 | 0.46 | 65.7 | 45.9-93.9 | 1.1 | 0.6-1.8 | 1.0 | 0.6-1.7 |
| Active surgery# | ||||||||
| Local disease | 26 | 0.92 | 28.1 | 19.2-41.3 | Ref | Ref | ||
| Regional disease | 9 | 0.52 | 17.2 | 8.9-33.0 | 0.6 | 0.3-1.3 | 0.6 | 0.3-1.4 |
| Distant metastases | —¶ | —¶ | 24.2 | 3.4-171.5 | 0.9 | 0.1-6.4 | 0.8 | 0.1-5.7 |
| Unknown | 14 | 0.65 | 21.5 | 12.7-36.3 | 0.8 | 0.4-1.5 | 0.7 | 0.4-1.4 |
Divided by 1000.
Per 1000 person-years.
Adjusted for grade, endocrine therapy, BMI, comorbidity (Charlson score), and age. These variables were fitted using the same categorization as in multivariable models presented in Table 2.
Cohort time during which participants are not at risk as a result of surgery or chemotherapy.
During chemotherapy and for the 2 months after completion of therapy. Excludes person-time during which participants are at risk after surgery.
Number of outcome events and person-time are censored for cell frequencies <5, in line with CPRD policy.
During surgery and for the first 2 months after discharge from the surgical hospital. Excludes person-time during which participants are at risk during or after chemotherapy.